In vitro models of age-related neurodegenerative disorders

Experimental Gerontology

Volumn 38, Issue 11-12, 2003, Pages 1309-1317

  Delacourte, André ^a   Sergeant, Nicolas ^a   Buée, Luc ^a  

^a INSERM   (France)

Author keywords

Aging; Alzheimer's disease; Neurodegenerative disorder

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN; PROTEIN TAU; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; DEMENTIA; FRONTAL LOBE; GLIA CELL; GLUCOSE METABOLISM; HUMAN; LEWY BODY; MOLECULAR MODEL; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSONISM; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0346786305     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2003.09.010     Document Type: Article

References (59)

1. Alves Da Costa C., Paitel E., Vincent B., Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277:2002;50980-50984.
2. Ancolio K., Dumanchin C., Barelli H., Warter J.M., Brice A., Campion D., Frebourg T., Checler F. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715→Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc. Natl Acad. Sci. USA. 96:1999;4119-4124.
3. Ando K., Iijima K.I., Elliott J.I., Kirino Y., Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J. Biol. Chem. 276:2001;40353-40361.
4. Brun A., Gustafson L., Passant U. A new kind of degenerative dementia. Localization, rather than type is significant in frontal lobe dementia. Lakartidningen. 91:1994;4751-4757.
5. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33:2000;95-130.
6. Bussiere T., Hof P.R., Mailliot C., Brown C.D., Caillet-Boudin M.L., Perl D.P., Buee L., Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol. (Berl.). 97:1999;221-230.
7. Buxbaum J.D., Koo E.H., Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl Acad. Sci. USA. 90:1993;9195-9198.
8. Cescato R., Dumermuth E., Spiess M., Paganetti P.A. Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis. J. Neurochem. 74:2000;1131-1139.
9. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
10. De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C., De Strooper B. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10:2001;1665-1671.
11. Delacourte A., Buee L. Tau pathology: a marker of neurodegenerative disorders. Curr. Opin. Neurol. 13:2000;371-376.
12. Delacourte A., David J.P., Sergeant N., Buee L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., Petit H., Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 52:1999;1158-1165.
13. Delacourte A., Sergeant N., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp. Gerontol. 37:2002;1291-1296.
14. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 59:2002;398-407.
15. Delobel P., Flament S., Hamdane M., Jakes R., Rousseau A., Delacourte A., Vilain J.P., Goedert M., Buee L. Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation. J. Biol. Chem. 277:2002;9199-9205.
16. Delobel P., Flament S., Hamdane M., Mailliot C., Sambo A.V., Begard S., Sergeant N., Delacourte A., Vilain J.P., Buee L. Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis. J. Neurochem. 83:2002;412-420.
17. DeTure M., Ko L.W., Easson C., Yen S.H. Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am. J. Pathol. 161:2002;1711-1722.
18. DeTure M.A., Di Noto L., Purich D.L. In vitro assembly of Alzheimer-like filaments. How a small cluster of charged residues in Tau and MAP2 controls filament morphology. J. Biol. Chem. 277:2002;34755-34759.
19. Dickson D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14:2001;423-432.
20. Duyckaerts C., Hauw J.J. Diagnosis and staging of Alzheimer disease. Neurobiol. Aging. 18:1997;S33-S42.
21. Gandy S., Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie. 76:1994;300-303.
22. Gandy S.E., Caporaso G.L., Buxbaum J.D., de Cruz Silva O., Iverfeldt K., Nordstedt C., Suzuki T., Czernik A.J., Nairn A.C., Greengard P. Protein phosphorylation regulates relative utilization of processing pathways for Alzheimer beta/A4 amyloid precursor protein. Ann. NY Acad. Sci. 695:1993;117-121.
23. Gillespie S.L., Golde T.E., Younkin S.G. Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation. Biochem. Biophys. Res. Commun. 187:1992;1285-1290.
24. Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 8:1992;159-168.
25. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., Cha J.H., Newell K., Miller D.W., Ueda K., Young A.B., Hyman B.T., Ashe K.H. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging. 24:2003;245-258.
26. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 293:2001;1491-1495.
27. Hall G.F., Lee V.M., Lee G., Yao J. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am. J. Pathol. 158:2001;235-246.
28. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 369:1994;488-491.
29. Holzer M., Bruckner M.K., Beck M., Bigl V., Arendt T. Modulation of APP processing and secretion by okadaic acid in primary guinea pig neurons. J. Neural Transm. 107:2000;451-461.
30. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345:1994;27-32.
31. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
32. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:2001;1121-1159.
33. Mailliot C., Bussiere T., Caillet-Boudin M.L., Delacourte A., Buee L. Alzheimer-specific epitope of AT100 in transfected cell lines with tau: toward an efficient cell model of tau abnormal phosphorylation. Neurosci. Lett. 255:1998;13-16.
34. Mailliot C., Sergeant N., Bussiere T., Caillet-Boudin M.L., Delacourte A., Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett. 433:1998;201-204.
35. Mailliot C., Podevin-Dimster V., Rosenthal R.E., Sergeant N., Delacourte A., Fiskum G., Buee L. Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. 20:2000;543-549.
36. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
37. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8:2001;535-539.
38. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 47:1996;1113-1124.
39. McKeith I.G., Perry E.K., Perry R.H. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 53:1999;902-905.
40. McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 58:2001;1803-1809.
41. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 270:1995;23895-23898.
42. Planel E., Yasutake K., Fujita S.C., Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 276:2001;34298-34306.
43. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
44. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20:2000;6021-6029.
45. Russo C., Violani E., Salis S., Venezia V., Dolcini V., Damonte G., Benatti U., D'Arrigo C., Patrone E., Carlo P., Schettini G. Pyroglutamate- modified amyloid beta-peptides - AbetaN3(pE) - strongly affect cultured neuron and astrocyte survival. J. Neurochem. 82:2002;1480-1489.
46. Schultz C., Hubbard G.B., Tredici K.D., Braak E., Braak H. Tau pathology in neurons and glial cells of aged baboons. Adv. Exp. Med. Biol. 487:2001;59-69.
47. Sergeant N., David J.P., Goedert M., Jakes R., Vermersch P., Buee L., Lefranc D., Wattez A., Delacourte A. Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J. Neurochem. 69:1997;834-844.
48. Sergeant N., David J.P., Champain D., Ghestem A., Wattez A., Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J. Neurochem. 81:2002;663-672.
49. Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H., Kostanjevecki, V., Missiaen, C., Wattez, A., David, J.P., Vanmechelen, E., Sergheraert, C., Delacourte, A., 2003. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 85(6), 1581-1591.
50. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA. 97:2000;4897-4902.
51. Shirotani K., Tsubuki S., Lee H.J., Maruyama K., Saido T.C. Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons. Neurosci. Lett. 327:2002;25-28.
52. Sommer B., Barbieri S., Hofele K., Wiederhold K., Probst A., Mistl C., Danner S., Kauffmann S., Spooren W., Tolnay M., Bilbe G., van der Putten H., Kafmann S., Caromi P., Ruegg M.A. Mouse models of alpha-synucleinopathy and Lewy pathology. Exp. Gerontol. 35:2000;1389-1403.
53. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54:2002;469-525.
54. Sun X., Cole G.M., Chu T., Xia W., Galasko D., Yamaguchi H., Tanemura K., Frautschy S.A., Takashima A. Intracellular Abeta is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines. Neurobiol. Aging. 23:2002;195-203.
55. Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl Acad. Sci. USA. 99:2002;13896-13901.
56. Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease? J. Cell Biol. 132:1996;413-425.
57. Wilhelmsen K.C., Lynch T., Pavlou E., Higgins M., Nygaard T.G. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am. J. Hum. Genet. 55:1994;1159-1165.
58. Zhukareva V., Vogelsberg-Ragaglia V., Van Deerlin V.M., Bruce J., Shuck T., Grossman M., Clark C.M., Arnold S.E., Masliah E., Galasko D., Trojanowski J.Q., Lee V.M. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol. 49:2001;165-175.
59. Zhukareva V., Sundarraj S., Mann D., Sjogren M., Blenow K., Clark C.M., McKeel D.W., Goate A., Lippa C.F., Vonsattel J.P., Growdon J.H., Trojanowski J.Q., Lee V.M. Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol. (Berl.). 105:2003;469-476.